Penumbra (PEN) Cash from Operations Growth (1y) (2015 - 2026)
Penumbra (PEN) Cash from Operations Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -84.38% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 185.96% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 122.43% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 16.00% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Penumbra | 12.48 Bn | 11.87 Bn | 253.41 Mn | 77.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 77.60% |
| Dec 31, 2025 | 69.22% |
| Sep 30, 2025 | 3.18% |
| Jun 30, 2025 | 98.78% |
| Mar 31, 2025 | 27.88% |
| Dec 31, 2024 | 40.94% |
| Sep 30, 2024 | 83.07% |
| Jun 30, 2024 | 32.24% |
| Mar 31, 2024 | 191.68% |
| Dec 31, 2023 | 2,612.12% |
| Sep 30, 2023 | 338.93% |
| Jun 30, 2023 | 143.21% |
| Mar 31, 2023 | 390.85% |
| Dec 31, 2022 | 114.42% |
| Sep 30, 2022 | -135.42% |
| Jun 30, 2022 | -1,095.62% |
| Mar 31, 2022 | 68.58% |
| Dec 31, 2021 | -345.03% |
| Sep 30, 2021 | 1,126.76% |
| Jun 30, 2021 | 84.74% |